Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 101 to 150 of 372

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Total hip arthroplasty using the superpath approach for osteoarthritis	Interventional procedures guidance	TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]	Technology appraisal guidance	TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]	Technology appraisal guidance	TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]	Technology appraisal guidance	TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Asunercept for treating glioblastoma [1301]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]	Technology appraisal guidance	TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]	Technology appraisal guidance	TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629	Technology appraisal guidance	TBC
Managing common infections - antimicrobial prescribing guidelines	NICE guideline	TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests	Diagnostics guidance	TBC
Pralsetinib for thyroid cancer [ID4018]	Technology appraisal guidance	TBC
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]	Highly specialised technology	TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]	Technology appraisal guidance	TBC
Peezy Midstream for urine collection (MT446)	Medical technologies guidance	TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533	Technology appraisal guidance	TBC
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]	Technology appraisal guidance	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]	Technology appraisal guidance	TBC
Insertion of neo-chordae into the beating heart for mitral regurgitation	Interventional procedures guidance	TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain	Medical technologies guidance	TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance	TBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]	Technology appraisal guidance	TBC
Ibrutinib for untreated mantle cell lymphoma [ID1221]	Technology appraisal guidance	TBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)	Medical technologies guidance	TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]	Technology appraisal guidance	TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]	Technology appraisal guidance	TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]	Technology appraisal guidance	TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]	Technology appraisal guidance	TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]	Technology appraisal guidance	TBC

Results per page

10
25
50
All